Abstract Details

MRI Signature of Neuromelanin and Iron Pathology in Parkinson's Disease
Movement Disorders
P6 - Poster Session 6 (11:30 AM-1:00 PM)
15-023

Parkinson’s disease (PD) pathology is characterized by neuromelanin loss and iron accumulation in substantia nigra pars compacta (SNc), as well as profound locus coeruleus (LC) degeneration. We have shown previously that neuromelanin-sensitive and iron-sensitive MRI sequences can robustly detect and quantify these phenomena (Huddleston DE, et al, 2017, PMID:28240402; Langley J, et al, 2017, PMID:27687624). No validated biomarkers for PD exist, and clinical diagnostic accuracy is sub-optimal in clinico-pathologic correlation studies. Neuroimaging tools are urgently needed to confirm PD neuropathology, assist clinical diagnosis, and enhance clinical trial recruitment.

To develop a multivariable signature to assist Parkinson’s disease diagnosis.

67 individuals (36 PD, 31 control) were studied at the Emory Movement Disorders Clinic under an IRB approved protocol with informed, written consent. MRI data were acquired using a Siemens Prisma-Fit 3T scanner. Neuromelanin-sensitive MRI (NM-MRI) and R2* (iron-sensitive MRI) acquisition and automated image processing to extract relevant features in SNc and LC were done using published methods (Langley J, et al, 2017, PMID: 27687624; Huddleston DE, et al, 2017, PMID: 28240402). The Movement Disorders Society UPDRS (MDS-UPDRS) Parts I and II questionnaires, the REM Sleep Behavior Disorder Questionnaire (RBDQ) and the Non-Motor Symptoms Questionnaire (NMSQ) were collected. With this dataset of extracted MRI and clinical features, logistic regression with elastic net (with 10-fold cross-validation) was used to train a classifier to accurately differentiate PD from controls. Sensitivity analysis was performed to identify informative features.

In a model including 6 MRI features of neuromelanin and iron pathology and 6 clinical features, receiver operating characteristic analysis revealed 94.2% diagnostic accuracy. Sensitivity analysis identified SNc volume, SNc R2*, MDS-UPDRS-II total score, and RBDQ item 2 (aggressive, action-packed dreams? yes/no) as the most informative features.

This multivariable profile exhibits diagnostic accuracy in a potentially useful range for clinical and translational applications, and warrants further development.

Authors/Disclosures
Daniel Huddleston, MD (Emory University)
PRESENTER
The institution of Dr. Huddleston has received research support from NIH-NINDS 1K23NS105944-01A1. The institution of Dr. Huddleston has received research support from Michael J. Fox Foundation (MJFF-010556). The institution of Dr. Huddleston has received research support from Lewy Body Dementia Association Research Center of Excellence (Emory). The institution of Dr. Huddleston has received research support from American Parkinson's Disease Association.
No disclosure on file
No disclosure on file
Stewart A. Factor, DO, FAAN (Emory University School of Medicine) Dr. Factor has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Factor has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Factor has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. The institution of Dr. Factor has received research support from Biohaven. The institution of Dr. Factor has received research support from Voyager. The institution of Dr. Factor has received research support from Neurocrine. The institution of Dr. Factor has received research support from Supernus. The institution of Dr. Factor has received research support from Prelinia. The institution of Dr. Factor has received research support from Medtronics. The institution of Dr. Factor has received research support from Boston Scientific. The institution of Dr. Factor has received research support from Sun Pharmaceuticals Advanced Research Company. The institution of Dr. Factor has received research support from Aspen. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file